Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Eggers, Maren ^a   Terletskaia Ladwig, Elena ^a   Rabenau, Holger F ^b   Doerr, Hans W ^b   Diedrich, Sabine ^c   Enders, Gisela ^a   Enders, Martin ^a  

^a Infectious Diseases and Epidemiology eV   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CHAT POLIOMYELITIS VIRUS 1; CHILD; CONTROLLED STUDY; GERMANY; HUMAN; IMMUNIZATION; NONHUMAN; POLIOMYELITIS VIRUS 1; PRACTICE GUIDELINE; SABIN POLIOMYELITIS VIRUS 1; SCHOOL CHILD; SEROLOGY; VACCINATION; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; WORLD HEALTH ORGANIZATION; BLOOD; IMMUNOLOGY; INFANT; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; SERODIAGNOSIS; VIROLOGY;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; GERMANY; HUMANS; INFANT; NEUTRALIZATION TESTS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES;

EID: 78649775822     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-347     Document Type: Article

References (25)

1. EN 14476:2007-02: Chemical disinfectants and antiseptics - Virucidal quantitative suspensiontest for chemical disinfectants and antiseptics used in human medicine - Test method and requirements (phase 2/step 1). 2007,
2. Cabasso VJ, Jervis G, Moyer AW, Roca-Garcia M, Orsi EV, Cox HR. Cumulative testing experience with consecutive lots of oral poliomyelitis vaccine. p. 102-134. In Live poliovirus vaccines. First International Conference on Live Poliovirus Vaccines. Scientific publication no. 44. Pan American Sanitary Bureau. Washington. D.C 1959,
3. Sabin AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccines. J Biol Stand 1973, 1:115-118.
4. Martín J, Minor PD. Characterization of CHAT and Cox type 1 live-attenuated poliovirus vaccine strains. J Virol 2002, 76(11):5339-49. 137059, 11991962.
5. Melnick JL. Problems associated with the use of live poliovirus vaccine. Am J Public Health Nations Health 1960, 50:1013-31. 10.2105/AJPH.50.7.1013, 1373390, 13769275.
6. Cáceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 2001, 33(4):531-41.
7. Lidner U, Blume SS. Vaccine innovation and adoption: Polio vaccines in the UK. the Netherlands and West Germany. 1955-1965. Medical History 2006, 50:425-446. 1592614, 17066127.
8. Diedrich S, Claus H, Thierfelder W, Schreier E. Bundesgesundheitssurvey: Immunitätslage gegen Poliomyelitis. Dtsch Med Wschr 2000, 125(19):584-588. 10.1055/s-2007-1024365, 11320716.
9. Pebody R. Polio vaccination in Europe: the shift from OPV to IPV use. Euro Surveill 2004, 8(34):pii-2529., http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2529
10. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, Strebel PM, Cono J, Wharton M, Orenstein WA, Sutter RW. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004, 292(14):1696-701. 10.1001/jama.292.14.1696, 15479934.
11. Eggers M, Terletskaia-Ladwig E, Enders G, Enders M. Immunity status of laboratory workers against poliomyelitis virus type 1 strain CHAT and Sabin (LSc-2ab). Hyg Med 2009, 34(3):86-89.
12. WHO Manual for the virological investigation of polio. Geneva: World Health Organization 1997, (WHO/EPI/GEN/97.01), WHO.
13. Diedrich S, Claus H, Schreier E. Immunity status against poliomyelitis in Germany: determination of cut-off values in International Units. BMC Infect Dis 2002, 2:2. 10.1186/1471-2334-2-2, 101379, 11943068.
14. Plotkin SA, Vidor E. Poliovirus vaccine--inactivated 2004, 605-29. Vaccines. Saunders. Orenstein, Plotkin SA, Walter A, 4.
15. Wood DJ, Heath AB. The Second International Standard for anti-poliovirus sera types 1, 2 and 3. Biologicals 1992, 20(3):203-11. 10.1016/S1045-1056(05)80039-9, 1333776.
16. Martin J, Crossland G, Wood DJ, Minor PD. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 2003, 84:1781-8. 10.1099/vir.0.19088-0, 12810872.
17. Rezapkin G, Martin J, Chumakov K. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method. Biologicals 2005, 33(1):29-39. Epub 2005 Jan 27, 10.1016/j.biologicals.2004.11.001, 15713554.
18. Robertson S. Module 6: Poliomyelitis. The Immunological Basis for Immunization Series. 1993, Geneva, WHO, WHO/EPI/GEN/93.16.
19. Gelfand HM, LeBLanc DR, Potash L, Fox JP. Studies on the development of natural immunity to poliomyelitis in Louisiana. IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am J Hyg 1959, 70:312-27.
20. Nishio O, Ishihara Y, Sakae K, Nonomura Y, Kuno A, Yasukawa S, Inoue H, Miyamura K, Kono R. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. J Biol Stand 1984, 12(1):1-10. 10.1016/S0092-1157(84)80015-3, 6699021.
21. McKay HW, Fodor AR, Kokko UP. Viremia Following the Administration of Live Poliovirus Vaccines. Am J Public Health Nations Health 1963, 53(2):274-85. 10.2105/AJPH.53.2.274, 1253906, 18017963.
22. WHO The Immunological Bass for Immunization Series. Module 56: Poliomyelitis. 1993, Geneva: World Health Organization, (WHO/EPI/GEN/93.16), WHO.
23. Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MA. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis 2005, 191(6):990-9. 10.1086/427810, 15717277.
24. WHO position paper Polio vaccines and polio immunization in the pre-eradication era. Wkly Epidemiol Rec 2010, 85(23):213-28. WHO position paper.
25. Dowdle WR, Gary HE, Sanders R, van Loon AM. Can post-eradication laboratory containment of wild polioviruses be achieved?. Bull World Health Organ 2002, 80(4):311-6. 2567771, 12075368.